Ibrance, Prevnar 13 Q2 Sales Validate Pfizer's R&D Investments
This article was originally published in The Pink Sheet Daily
Novel products help the company beat consensus estimates for the quarter, and the pharma giant pointed to immuno-oncology and PCSK9 as investments that will provide greater returns in the future. Additional acquisitions and a potential split remain on the table, execs say.
Register for our free email digests: